Ronald E. Bruehlman Joins GoodRx Board of Directors
28 Oktober 2024 - 1:00PM
Business Wire
IQVIA CFO brings 39 years of healthcare and
finance expertise to GoodRx
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our,"
“GoodRx” or the “Company”), the leading prescription savings
platform in the U.S., today announced the election of Ronald E.
Bruehlman to its Board of Directors, effective November 8, 2024.
Mr. Bruehlman brings to GoodRx 39 years of finance experience in
the healthcare services, industrial and petroleum industries. He
currently serves as Chief Financial Officer of IQVIA, a global
provider of advanced analytics, technology solutions, and contract
research. Prior to IQVIA, he served as CFO of IMS Health and had a
23-year career at United Technologies Corporation, where he held
multiple senior finance leadership roles of increasing
responsibility. Mr. Bruehlman previously served on the board of
directors of Atotech Ltd., Q-Squared Solutions, and Clipper
Windpower.
"We are thrilled to welcome Mr. Bruehlman to the GoodRx Board.
His extensive expertise leading financial strategies for public and
private healthcare and technology companies is a perfect match for
GoodRx as we navigate the complex healthcare market," said Trevor
Bezdek, GoodRx co-founder and Chairman of the Board. "Mr.
Bruehlman’s deep financial insight and strategic acumen will be
critical as we continue to focus on sustainable and profitable
revenue growth, aiming to enhance affordability and access to
prescription medications across the country. His leadership will
ensure the highest standards of financial management and strategic
risk assessment as we drive forward our mission.”
Mr. Bruehlman will also serve as the chairperson of the Board’s
Audit and Risk Committee, following Julie Bradley’s resignation as
a member of GoodRx’s Board of Directors effective on November 8,
2024.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (“SEC”) and public conference
calls and webcasts. The information contained on, or that may be
accessed through, GoodRx’s website is not incorporated by reference
into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding the anticipated contributions from Ronald E.
Bruehlman in his directorship and expected benefits to the Company
and our Board. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to,
risks relating to our ability to attract and retain talent and the
important factors discussed under the caption “Risk Factors” in
GoodRx’s Annual Report on Form 10-K for the year ended December 31,
2023, and our other filings with the SEC. Any such forward-looking
statements are based on current expectations, projections and
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241028840743/en/
Investor Contact ir@goodrx.com
Media Contact press@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024